Literature DB >> 3281493

Immunization trials with the ring-infected erythrocyte surface antigen of Plasmodium falciparum in owl monkeys (Aotus vociferans).

W E Collins1, M Pappaioanou, R F Anders, G H Campbell, G V Brown, D J Kemp, J R Broderson, R L Coppel, J C Skinner, P M Procell.   

Abstract

A protocol was developed for the testing of blood stage vaccines against Plasmodium falciparum using Peruvian Aotus vociferans and the Indochina I/CDC strain of the parasite. Three different fused polypeptide vaccines containing elements of the ring-infected erythrocyte surface antigen molecule combined with Freund's complete and Freund's incomplete adjuvants were tested to determine their ability to protect against overwhelming infection following challenge with this highly virulent strain of P. falciparum, and to invoke antibody responses as measured by a standard indirect immunofluorescence technique. Nine of 14 immunized animals exhibited some protection. Presented are the test procedures developed for the conduct of such trials with New World monkeys and the analysis of results that led to the identification of variables selected for study in future trials.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281493     DOI: 10.4269/ajtmh.1988.38.268

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  6 in total

1.  Rhoptry-associated protein 1-binding monoclonal antibody raised against a heterologous peptide sequence inhibits Plasmodium falciparum growth in vitro.

Authors:  R Moreno; F Pöltl-Frank; D Stüber; H Matile; M Mutz; N A Weiss; G Pluschke
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria.

Authors:  M Salcedo; L Barreto; M Rojas; R Moya; J Cote; M E Patarroyo
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

3.  Plasmodium falciparum ring-infected erythrocyte surface antigen is released from merozoite dense granules after erythrocyte invasion.

Authors:  J G Culvenor; K P Day; R F Anders
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

4.  Developing peptide based immunogen against human malaria delivered in liposomes containing non-toxic adjuvants.

Authors:  D N Rao; B Chaba; P Kumar; W Haq; L Sabhnani
Journal:  Indian J Clin Biochem       Date:  1997-12

Review 5.  Future potential of malaria vaccines.

Authors:  M Hommel
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

6.  Role of non-human primates in malaria vaccine development: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.